Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma
Douglas B. Johnson(Vanderbilt University Medical Center), Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Adil Daud(University of California, San Francisco), Svetlana B. McKee(University of Alabama at Birmingham), David L. Rimm(Yale University), Bashar Dabbas(Lineage Cell Therapeutics (United States)), Richard W. Joseph(Daiichi Sankyo (United States)), John S. Witte(University of California, San Francisco), Shabnam Tangri(Navidea Biopharmaceuticals (United States)), Joseph Markowitz(University of South Florida), Pauline Funchain(Palo Alto University), Thai H. Ho(Mayo Clinic in Arizona), James W. Smithy(Memorial Sloan Kettering Cancer Center), Robert M. Conry(University of Alabama), Anastasios Dimou(Mayo Clinic), Christine Vaupel(Navidea Biopharmaceuticals (United States)), Jennifer S. Ko(Cleveland Clinic), Justin M. Balko(Vanderbilt University Medical Center), Leonel F. Hernandez‐Aya(Washington University in St. Louis), Ju Young Kim(Lineage Cell Therapeutics (United States)), Elizabeth Gaughan(University of Virginia), Jeffrey M. Hall(Lineage Cell Therapeutics (United States)), John M. Wrangle(Medical University of South Carolina), Jelveh Lameh(Lineage Cell Therapeutics (United States))
Cited by 176
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k